Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 912 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR Mental Health Awareness for Health Care Providers May 21, 2021 Patients less likely to rate cancer care as ‘very good’ during... August 4, 2021 ΙΣΤΟΡΙΑ January 18, 2019 Epigenetic Information Could Harbour Biomarkers of Diagnosis and Prognosis September 15, 2025 Load more HOT NEWS NCI Expands Repository of Cancer Research Models: A Conversation with Drs.... Brain Cancer Cells Hijack Gene “On Switches” to Drive Tumor Growth Concurrent Intrathecal and Intravenous Nivolumab is Safe and Feasible with Preliminary... Little Girl Declared Cancer-Free For The Holidays Following 2 Years Of...
